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Aims: To compare the effects of initiating insulin as a fourth-line antidiabetic therapy with the
effects of enhancing oral antidiabetic drug (OAD) therapy in patients with type 2 diabetes melli-
tus (T2DM) with triple OAD therapy failure.
Materials and methods: We conducted a nationwide population-based, retrospective cohort
study involving 1022 (without prevalent diabetes-related complications [PDRCs]) and 2077
(with/without PDRCs) propensity score-matched pairs of fourth-line insulin therapy users and
enhanced OAD therapy users identified in the period 2004 to 2010. Clinical outcomes including
a composite cardiovascular outcome (myocardial infarction, stroke, heart failure or ischaemic
heart disease), peripheral vascular disease (PVD), hypoglycaemia and all-cause mortality were
assessed up to 2013. Hypoglycaemia was adjusted in Cox models to consider its potential effect
on study outcomes.
Results: In a T2DM cohort without PDRCs, fourth-line insulin therapy was not associated with
greater risks of clinical outcomes, except hypoglycaemia (hazard ratio [HR] 1.45, 95% confi-
dence interval [CI] 1.02-2.07), compared with enhanced OAD therapy. Among patients with
T2DM with/without PDRCs, fourth-line insulin therapy was associated with greater risks of the
composite cardiovascular outcome (HR 1.23, 95% CI 1.03-1.46), heart failure (HR 1.59, 95% CI
1.12-2.25), ischaemic heart disease (HR 1.37, 95% CI 1.09-1.73), PVD (HR 1.17, 95% CI
1.00-1.36), hypoglycaemia (HR 1.49, 95% CI 1.20-1.85) and all-cause mortality (HR 1.48, 95%
CI 1.01-2.17), but adjustment for hypoglycaemia significantly attenuated the risk of heart failure
(HR 1.34, 95% CI 0.92-1.94), PVD (HR 1.15, 95% CI 0.98-1.34) and all-cause mortality (HR 1.30,
95% CI 0.84-1.99).
Conclusions: Initiation of fourth-line insulin therapy can be considered for patients with T2DM
with triple OAD therapy failure, and the importance of awareness and prevention of hypogly-
caemia among insulin-treated patients with T2DM cannot be overstated.
KEYWORDS
antidiabetic drug, cardiovascular disease, cohort study, hypoglycaemia, insulin therapy, type
2 diabetes
1 | INTRODUCTION
Early insulin initiation is suggested to preserve β-cell function,1–3 but
in real-world clinical practice insulin is still commonly prescribed at a
later stage of an antidiabetic treatment course because of clinical iner-
tia.4 Most patients with type 2 diabetes mellitus (T2DM) generally do
not begin insulin therapy until they have experienced poor glycaemic
control using three oral antidiabetic drugs (OADs).5 Insulin initiation is
often delayed or patients have poor adherence to insulin therapy
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because of their fears about difficulty with injections, weight gain and
hypoglycaemia.6–8 Clinicians may have concerns about the safety pro-
file and unfavourable clinical outcomes of insulin, and thus they
choose to either maximize doses of three OADs or add another OAD
as enhanced OAD therapy for patients with triple OAD therapy fail-
ure, regardless of the clear recommendation by the American Diabe-
tes Association (ADA)9 to initiate insulin therapy for these patients.
Current evidence from randomized controlled trials (RCTs) and lon-
gitudinal cohort studies on the cardiovascular outcomes of insulin ther-
apy in patients with T2DM appears controversial. Favourable
cardiovascular outcomes of intensive glycaemic control using sulphony-
lureas or insulin versus conventional therapy using diet control were
documented in the 10-year follow-up UK Prospective Diabetes Study10;
however, other RCTs either showed no significant benefits of insulin
therapy on cardiovascular outcomes11,12 or revealed a link between
insulin-based therapy and a greater number of non-fatal cardiovascular
events.13 Recently, two meta-analyses of RCTs suggested a neutral
effect of insulin therapy on cardiovascular outcomes.14,15 These study
findings should be interpreted with caution, however, because the stud-
ies included a limited number of cardiovascular events and shorter
follow-up periods, the sulphonylureas used10,12 might also have had det-
rimental effects on cardiovascular disease (CVD),16 and the study popu-
lations were specific to either patients at an early stage of diabetes11 or
those with existing CVD.12,13 Conversely, longitudinal cohort studies
have shown an association between insulin therapy and increased risk
of CVD and all-cause mortality in patients with T2DM, but the effects
of insulin therapy were only assessed in patients at an early stage of the
antidiabetic treatment course, with insulin being used as monotherapy,
or as second-line or third-line antidiabetic treatment.17–24
Because T2DM is a progressive disease, most patients with T2DM
eventually require insulin therapy. Although it is quite common in real-
world clinical practice for insulin therapy to be initiated at a later stage
of an antidiabetic treatment course, the effects of insulin used as a
fourth-line antidiabetic treatment in patients with T2DM who have
failed to achieve glycaemic control on triple OAD therapy remain
unknown. The aim of the present study, therefore, was first to investi-
gate the risk of clinical outcomes associated with intensifying triple
OAD therapy by initiating insulin (ie, in fourth-line insulin users) versus
those of enhancing OAD therapy (ie, in potential insulin use candidates
[PICs]). Second, we sought to determine whether hypoglycaemia played
a role in the relationship between insulin use and clinical outcomes.
Hypoglycaemia has been shown to contribute to the risk of developing
CVD25–27; thus, we hypothesized that the increased hypoglycaemia
associated with insulin therapy might negatively impact the association
between insulin therapy and clinical outcomes. Third, as basal insulin
alone is recommended as the initial insulin regimen by the ADA,9 we
performed subgroup analyses to investigate whether the effects of
insulin therapy differed according to insulin regimen.
2 | MATERIALS AND METHODS
This study was conducted with permission from the Institutional
Review Board of National Cheng Kung University Hospital (B-EX-
103-015).
2.1 | Data source
This was a retrospective cohort study using the Longitudinal Cohort
of Diabetes Patients (LHDB) dataset for 1996 to 2013 from Taiwan's
National Health Insurance Research Database (NHIRD) that was
released by Taiwan's National Health Research Institutes. The NHIRD
is population based and derived from claims data of the National
Health Insurance (NHI) programme, a mandatory-enrolment, single-
payment system that covers >99% of Taiwan's population.28 The
LHDB is a national representative dataset for the population of
patients with diabetes in Taiwan and has been validated by Taiwan's
National Health Research Institutes for research purposes.29 This
dataset consists of longitudinal data (eg, disease diagnosis and pre-
scription utilization records) from a random sample of 120 000 de-
identified incident diabetes cases from each calendar year since 1999,
which were tracked back to 1996 and followed up to 2013.
2.2 | Study population
Study patients extracted from the LHDB were newly diagnosed with
T2DM (International Classification of Diseases, ninth revision, Clinical
Modification [ICD-9-CM] codes: 250.x0, 250.x2, x = 0-9) for the
period 1999 to 2010. We excluded those aged <18 years, and those
diagnosed with type 1 diabetes or gestational diabetes. The study
cohort selection process is detailed in Figure S1.
2.3 | Exposure to antidiabetic drugs
The World Health Organization Anatomical Therapeutic Chemical
Classification System was used to define antidiabetic drugs in the
LHDB. The LHDB in 2004 to 2010 was used to identify the treatment
exposure of interest. This period was chosen because long-acting
insulin analogues (LAIAs) were reimbursed by the NHI programme
from 2004, and ending the study period in 2010 allowed a follow-up
period of at least 3 years (ie, 2011-2013). During 2004 to 2010, the
index date for the fourth-line insulin group was defined as the first
date of initiating fourth-line insulin prescription for triple OAD ther-
apy regimens, and the index date for the PIC group was the first date
of enhancing OAD therapy by either increasing three OADs up to
maximal doses or adding a fourth-line OAD. Before the index date, all
patients in the two study groups were on sub-maximal doses of at
least one of three OADs. Type of insulin was confirmed by labels and
drug licensing codes (Table S1). Maximal doses of OADs were defined
according to information provided by drug product labels (Table S2).
2.4 | Definition of clinical outcomes
Primary outcomes included a composite outcome of non-fatal/fatal
CVD (ie, myocardial infarction [MI], cerebrovascular disease, heart fail-
ure or ischaemic heart disease) and all-cause mortality. Secondary out-
comes included individual CVD events, peripheral vascular disease
(PVD) and hypoglycaemia. Using the ICD-9-CM codes, events of hos-
pitalization for CVD and PVD were identified from the inpatient
claims files, and events of hypoglycaemia were identified from the
emergency department, inpatient and outpatient claims files
(Table S3). The accuracy of disease diagnoses based on ICD-9-CM
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coding in the NHIRD has been validated in previous studies.30–35 For
example, the positive predictive value for the diagnosis of myocardial
infarction, ischaemic stroke and heart failure has been reported to be
as high as 93%, 94% and 98%, respectively. In addition, hypoglycae-
mic events were ascertained according to the validated definition (ie,
having any of the following ICD-9-CM codes: 251.0, 251.1, 251.2,
250.3, 250.8 or 962.3).36,37 The operational definitions for confirming
mortality status have also been validated and described in previous
studies.38,39
2.5 | Statistical analyses
Primary analyses of baseline complication-free patients were con-
ducted on an intention-to-treat basis, where the follow-up for
patients was from the index date until death, dropout or loss to
follow-up from the NHI programme, occurrence of study outcomes,
or the end of 2013, whichever came first. Considering confounding by
indication and selection bias, one-to-one five-digit greedy propensity-
score matching (PSM)40,41 was used to adjust for imbalanced patient
characteristics between study groups, in which treatment status was a
dependent variable and a comprehensive list of independent variables
(Table 1, Table S4)37,42 was selected a priori based on clinical impor-
tance related to selection of antidiabetic drug regimens and study out-
comes. The variables used for the PSM included demographics,
comorbidities, diabetes-related complications, antidiabetic drugs and
CVD-related medications. Standardized mean difference (SMD) was
used to test the difference in patient characteristics between study
groups, and an absolute value of SMD > 0.1 indicated statistically sig-
nificant imbalance of patient characteristics between study
groups.43–45
The incidence rate of study outcomes was calculated as the total
number of events over the follow-up period divided by the number of
person-years at risk. Cox proportional hazards models were used to
compare risks of study outcomes between two propensity-score-
matched cohorts. Hazard ratios (HRs) and two-tailed 95% confidence
intervals (CIs) were computed. A two-tailed P value of <0.05 was con-
sidered statistically significant. Cumulative sums of martingale-based
residuals were used to check the proportional hazard assumption in
Cox models.46 To consider the potential effect of hypoglycaemia on
study outcomes, we adjusted for the presence of hypoglycaemia after
the index date as a covariate in Cox models. Before adjustment for
hypoglycaemia, we assessed the total effect of the fourth-line insulin
therapy versus the enhanced OAD therapy on risks of CVDs and
death, while after adjustment for hypoglycaemia, we assessed the
remaining effect of the fourth-line insulin therapy after the partial
effect of hypoglycaemia was considered. Akaike's information crite-
rion (AIC) was used to evaluate the quality of model fit between
models with and without adjustment for hypoglycaemia; a model with
a lower AIC had a better fit.
Secondary analyses were conducted in a larger cohort incorporat-
ing the study cohort for primary analyses with those patients having
prevalent diabetes-related complications (PDRCs) at baseline (1 year
before index date). History of PRDCs was additionally considered in
the PSM procedure. This analysis was conducted with the consider-
ation that some patients with T2DM may have already had comorbid
diseases before initiating insulin, and thus the secondary analysis
results could be generalizable to the T2DM population in real-world
clinical practice.
Sensitivity and subgroup analyses were performed using the
study cohort for primary analyses. First, as-treated scenario analysis
was conducted to account for over-estimation of the treatment effect
from primary analyses, where non-adherence to medications was
ignored. In addition to the censored definitions in primary analyses,
patients were also censored when medication treatment patterns
changed. Second, we redefined maximal doses of OADs according to
clinicians' discretion/recommendations (Table S2) in selecting the PIC
group to account for the real-world clinical practice variation in using
maximal doses of OADs. Third, we refined the definitions for stable
users of fourth-line insulin or enhanced OAD therapy by adding
another criterion that fourth-line insulin or enhanced OAD therapy
needed to last for at least 180 days after the index date. Fourth, com-
pared with enhanced OAD therapy, subgroup analyses were con-
ducted to evaluate the effects of different fourth-line insulin initiation
regimens, including basal insulin (ie, intermediate-acting human insulin
or LAIAs) alone and LAIAs alone. SAS software (version 9.4) was used
for all analyses.
3 | RESULTS
3.1 | Study cohort characteristics
We identified 3959 complication-free patients, with 1186 in the
fourth-line insulin group and 2773 in the PIC group (Figure S1).
Table 1 shows patient characteristics by study group. After PSM, we
included 1022 patients in each group for primary analyses; there was
no statistical difference in patient characteristics between treatment
groups. Table S5 shows the follow-up time for each study outcome in
primary analyses.
3.2 | Primary analyses
The HR of fourth-line insulin users versus PICs was 1.37 (95% CI
0.99-1.89) and 1.53 (95% CI 0.80-2.94) for the composite outcome of
CVD and all-cause death, respectively (Table 2). The HR for individual
CVD events ranged from 0.67 (95% CI 0.27-1.63) for MI to 1.64 (95%
CI 0.77-3.46) for heart failure. The HR was 1.20 (95% CI 0.91-1.58)
and 1.45 (95% CI 1.02-2.07) for PVD and hypoglycaemia, respectively.
Adjustment for hypoglycaemia significantly reduced HRs for most
study outcomes, eg, the HR decreased by 20%, from 1.53 to 1.23, for
all-cause death. Hypoglycaemia-adjusted Cox models yielded lower
AIC values for all study outcomes. Table S6 shows that the fourth-line
insulin group had a higher proportion of experiencing hypoglycaemia.
3.3 | Secondary analyses
In secondary analyses, we identified 2077 patients with T2DM with
or without PDRCs in each group after PSM; there was no statistical
difference in patient characteristics between groups (Table S4). The
HR of fourth-line insulin users versus PICs was significantly increased
for the composite outcome of CVD (1.23, 95% CI 1.03-1.46), heart
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TABLE 1 Patient characteristics of fourth-line insulin users (fourth-line insulin) and potential insulin use candidates before and after
propensity-score matching (primary analysis: Complication-free study cohorta)
Baseline characteristics
Before PSM After PSM
Fourth-line insulin,
n = 1186
PICs,
n = 2773 SMDb
Fourth-line insulin,
n = 1022
PICs,
n = 1022 SMDb
Mean  SD age, years 50.97  11.67 53.22  10.73 −0.20 51.51  11.65 51.46  10.42 0.00
Women, % 39.04 41.90 −0.06 39.24 39.14 0.00
Year of index datec, %
2004 4.38 6.35 −0.09 4.79 5.48 −0.03
2005 6.66 5.12 0.07 6.26 5.97 0.01
2006 9.27 10.31 −0.03 10.37 9.00 0.05
2007 18.47 11.86 0.18 15.26 15.56 −0.01
2008 19.22 14.57 0.12 17.81 18.49 −0.02
2009 23.02 25.17 −0.05 24.56 23.87 0.02
2010 18.97 26.61 −0.18 20.94 21.62 −0.02
Mean  SD diabetes durationd,
years
5.58  2.69 5.36  2.58 0.08 5.53  2.69 5.59  2.54 −0.02
Medical history in past 1 year, %
Hypertension 44.18 52.58 −0.17 46.09 46.87 −0.02
Dyslipidaemia 60.03 60.19 −0.00 60.67 60.18 0.01
Diabetic ketoacidosis 1.69 0.40 0.13 0.98 1.08 −0.01
Hyperosmolar hyperglycaemic
state
0.42 0.07 0.07 0.39 0.20 0.04
Hypoglycaemia 1.01 0.69 0.04 1.08 1.17 −0.01
Depression 1.43 1.08 0.03 1.57 1.47 0.01
CIC category, %
Cancer 5.65 3.28 0.11 4.89 5.28 −0.02
Gastrointestinal 27.66 24.45 0.07 27.20 27.98 −0.02
Musculoskeletal 26.14 29.07 −0.07 26.03 27.98 −0.04
Pulmonary 6.49 4.65 0.08 5.68 5.87 −0.01
Substance abuse 2.61 1.30 0.10 2.15 2.25 −0.01
Mental illness 6.91 5.19 0.07 6.75 8.12 −0.05
Drug history in past 1 year, %
OADs
Metformin 96.37 95.06 0.06 95.99 95.69 0.01
Sulphonylureas 95.78 94.37 0.07 95.30 95.79 −0.02
Meglitinides 8.60 8.69 −0.00 9.49 7.83 0.06
Thiazolidinediones 64.67 49.22 0.32 61.15 60.18 0.02
α-glucosidase inhibitors 38.79 54.17 −0.31 42.47 41.59 0.02
DPP-4 inhibitors 6.83 7.54 −0.03 7.14 8.71 −0.06
CVD-related medications
Lipid-modifying agents 53.04 56.04 −0.06 54.31 55.28 −0.02
α-blockers 2.19 2.38 −0.01 2.45 2.05 0.03
β-blockers 18.21 20.74 −0.06 18.59 16.63 0.05
RAAS agents 30.52 36.53 −0.13 30.63 32.49 −0.04
Diuretics 11.97 13.16 −0.04 12.13 10.47 0.05
Calcium channel blockers 21.67 30.65 −0.21 23.68 23.19 0.01
Class I and III antiarrhythmics 0.34 0.43 −0.02 0.29 0.49 −0.03
Digoxin 0.51 0.54 −0.00 0.59 0.29 0.04
Vasodilators 1.77 1.73 0.00 1.96 1.17 0.06
Antithrombotic agents 17.88 18.68 −0.02 18.40 16.73 0.04
Mean  SD HbA1c tests in past
1 year
3.26  1.80 3.07  1.89 0.11 3.23  1.83 3.37  1.94 −0.07
Pay for performance, % 34.91 17.85 0.39 29.06 28.28 0.02
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failure (1.59, 95% CI 1.12-2.25), ischaemic heart disease (1.37, 95% CI
1.09-1.73), PVD (1.17, 95% CI 1.00-1.36), hypoglycaemia (1.49, 95%
CI 1.20-1.85) and all-cause death (1.48, 95% CI 1.01-2.17). Likewise,
hypoglycaemia adjustment significantly reduced the HRs and yielded
lower AIC values for study outcomes. It is worth noting that the
hypoglycaemia-adjusted HRs were no longer statistically significant
for heart failure (1.34, 95% CI 0.92-1.94), PVD (1.15, 95% CI
0.98-1.34) and all-cause death (1.30, 95% CI 0.84-1.99 [Table S7]).
3.4 | Sensitivity and subgroup analyses
Results of sensitivity analyses (Tables S8–S10) were consistent with
those in primary analyses. In subgroup analyses, we selected two
subgroups from the fourth-line insulin group, including: (a) 598
patients who initiated basal insulin alone vs. 598 propensity-score-
matched PICs and (b) 517 patients who initiated LAIAs alone versus
517 propensity-score-matched PICs. The group of patients initiating
LAIAs alone was a subgroup of patients initiating basal insulin alone.
As shown in Table 3 and Tables S11 and S12, the HRs for each study
outcome were not statistically significant, except for hypoglycaemia
(1.45) in primary analyses, when comparing the entire fourth-line insu-
lin group with the propensity-score-matched PIC group. Notably,
however, there was an obvious decreased trend in HRs for the com-
posite CVD outcome, MI + cerebrovascular disease and PVD for
patients initiating any types of insulin, patients initiating basal insulin
alone and patients initiating LAIAs alone compared with their
TABLE 1 (Continued)
Baseline characteristics
Before PSM After PSM
Fourth-line insulin,
n = 1186
PICs,
n = 2773 SMDb
Fourth-line insulin,
n = 1022
PICs,
n = 1022 SMDb
Index agente prescriber's specialty, %
Family medicine 13.07 24.41 −0.29 15.07 15.66 −0.02
Endocrinology 58.35 29.10 0.62 52.15 50.78 0.03
Internal medicine 17.71 24.77 −0.17 20.35 22.21 −0.05
Cardiology 1.77 7.86 −0.29 2.05 2.35 −0.02
Nephrology 0.93 3.07 −0.15 1.08 1.37 −0.03
Abbreviations: CIC, chronic illness with complexity; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase-4; HbA1c, glycated haemoglobin; OAD, oral
antidiabetic drug; PIC, potential insulin use candidate; PSM, propensity-score matching; RAAS, renin-angiotensin-aldosterone system; SMD, standardized
mean difference.
a Complication-free study cohort is defined as patients without diabetes-related complications (a) at 1 year before index date and (b) before stable use of
fourth-line insulin in the fourth-line insulin users group and of enhanced OAD therapy in the PIC group.
b SMD > 0.1 or SMD < −0.1 indicates significant difference in baseline characteristics between fourth-line insulin and PIC groups.
c Index date is defined as the first date of insulin prescribed for fourth-line insulin users or the first date of three OADs' maximal doses reached/the first
date of fourth-line OAD added on for PICs.
d Diabetes duration was measured as the time from the first date of type 2 diabetes diagnosis to index date.
e Index agent is denoted as the first insulin prescription for fourth-line insulin users or the first prescription of three OADs' maximal doses reached/
fourth-line OAD added on for PICs.
TABLE 2 Incidence rates and hazard ratios of diabetes-related complications and death for fourth-line insulin users (fourth-line insulin) versus
potential insulin use candidates after propensity-score matching (primary analysis: Complication-free study cohorta)
Complications
Event/1000 person-years Akaike information criterion (AIC)
Fourth-line
insulin
(n = 1022)
PICs
(n = 1022)
Fourth-line insulin
vs PICs HR
(95% CI)
Hypoglycaemia-adjusted
HR (95% CI)
Without
adjustment for
hypoglycaemia
With adjustment
for
hypoglycaemia
CVD compositeb 23.26 17.46 1.37 (0.99-1.89) 1.29 (0.93-1.80) 211.73 199.26
MI 2.05 3.31 0.67 (0.27-1.63) 0.60 (0.22-1.65) 28.92 25.17
Cerebrovascular
diseases
10.20 7.03 1.40 (0.88-2.24) 1.18 (0.71-1.95) 99.80 88.15
MI + cerebrovascular
diseases
11.93 10.23 1.22 (0.81-1.86) 1.08 (0.69-1.70) 124.47 107.85
Heart failure 4.67 2.94 1.64 (0.77-3.46) 1.66 (0.74-3.70) 40.50 38.67
Ischaemic heart
diseases
10.43 8.96 1.20 (0.77-1.88) 1.24 (0.78-1.96) 108.11 105.97
PVD 26.52 23.98 1.20 (0.91-1.58) 1.16 (0.87-1.53) 277.64 274.03
Hypoglycaemia 20.26 13.80 1.45 (1.02-2.07) NA 171.03 NA
All-cause death 5.75 3.47 1.53 (0.80-2.94) 1.23 (0.59-2.56) 52.98 43.89
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; NA, not applicable; PIC, potential insulin use candidate; PVD,
peripheral vascular disease.
a Complication-free study cohort is defined as patients without diabetes-related complications (a) at 1 year before index date and (b) before stable use of
fourth-line insulin in the fourth-line insulin users group and of enhanced OAD therapy in the PIC group.
b CVD composite included myocardial infarction, cerebrovascular disease, heart failure, ischaemic heart disease, arrhythmia, arteriosclerotic CVD, aortic
aneurysm, cardiogenic shock and cardiac arrest.
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propensity-score-matched PIC group of patients; for example, the HR
for the composite CVD outcome decreased from 1.37 to 1.00 and
to 0.89.
4 | DISCUSSION
The ADA explicitly recommends insulin therapy for patients with
T2DM who have failed to achieve glycaemic control on triple ther-
apy.9 In current clinical practice, however, a high proportion of such
patients is still treated with either increasing doses of three OADs or
by adding another OAD instead of initiating fourth-line insulin ther-
apy. To our knowledge, this is the first large nationwide cohort study
to evaluate the effects of initiating fourth-line insulin therapy in a
real-world setting. First, we found that, in a T2DM cohort without
PDRCs, initiating fourth-line insulin versus enhancing OAD therapy
was not associated with increased risks of CVD, PVD or all-cause
mortality. Second, in a T2DM population with or without PDRCs,
fourth-line insulin was associated with increased risks of the compos-
ite outcome of CVD, heart failure, ischaemic heart disease, PVD and
all-cause mortality. Third, fourth-line insulin was associated with a
higher risk of hypoglycaemia than enhanced OAD therapy. Adjusting
for hypoglycaemia reduced the risks of study outcomes and yielded
lower AIC values of the models, suggesting that hypoglycaemia had a
significant effect on the association between insulin therapy and
increased CVD and all-cause mortality risks. Notably, among the
T2DM population with or without PDRCs, adjusting for hypoglycae-
mia would neutralize excess risks of heart failure, PVD and all-cause
mortality, which emphasizes the importance of awareness and pre-
vention of hypoglycaemia among insulin-treated patients with T2DM.
Fourth, compared with the propensity-score-matched PIC group, initi-
ation of fourth-line insulin therapy using LAIAs alone was associated
with a lower risk of the composite CVD outcome, MI + cerebrovascu-
lar disease and PVD.
4.1 | Effects of the fourth-line insulin versus
enhanced OAD therapy on clinical outcomes
The association of insulin therapy with incident CVD and mortality
has been investigated previously, but evidence is lacking on the
effects of initiating insulin as the fourth-line antidiabetic treatment
in patients with T2DM. Previous longitudinal studies evaluated the
effects of insulin when it was used as monotherapy,17,24 or second-
line17–21,24 or third-line22–24 treatment, and revealed a harmful
effect of insulin therapy on CVD and all-cause mortality. Unlike pre-
vious studies, we found that intensification of triple OAD therapy
by initiating fourth-line insulin versus enhancing OAD therapy was
not associated with increased risks of the composite or individual
outcomes of CVD, PVD or all-cause mortality in the complication-
free patients with T2DM, although it was associated with increased
risks of some clinical outcomes among patients with or without
PDRCs. Notably, one major concern in the previous studies is the
bias attributable to confounding by indication because those studies
compared insulin therapy with non-treatment,24 or metformin17,24
or sulphonylureas17 as monotherapy, or metformin + sulphonylur-
eas18,20,21 or metformin + dipeptidyl peptidase-4 (DPP-4) inibitors19
as dual therapy. Indeed, characteristics of insulin users are typically
different from patients without any treatment24 or those with only
one or two OADs.17–19,24 Unlike previous studies, we carefully
identified a comparable group to the insulin-treated group and
focused on evaluating the effects of fourth-line insulin therapy in
patients with T2DM who failed to achieve glycaemic control on tri-
ple OAD therapy; in other words, all of our study patients had been
candidates for insulin therapy. Moreover, we applied rigorous PSM
approaches and identified baseline complication-free patients for
primary analyses, which led to more comparable groups, minimized
confounding by indication, and ensured causal inference in our
study.
TABLE 3 Hazard ratios of diabetes-related complications and death for fourth-line insulin users, fourth-line basal insulin users, fourth-line
long-acting insulin analogue users vs. potential insulin use candidates after propensity-score matching (primary analysis: Complication-free study
cohorta)
Primary analysis Subgroup analysis
Complications
Fourth-line insulin users vs. PICs HR
(95% CI)
Fourth-line basal insulin users vs. PICs
HR (95% CI)
Fourth-line LAIA users vs. PICs
HR (95% CI)
CVD compositeb 1.37 (0.99-1.89) 1.00 (0.65-1.54) 0.89 (0.45-1.73)
MI + cerebrovascular
diseases
1.22 (0.81-1.86) 0.76 (0.42-1.38) 0.65 (0.23-1.87)
Peripheral vascular
diseases
1.20 (0.91-1.58) 1.14 (0.78-1.67) 1.01 (0.65-1.57)
Hypoglycaemia 1.45 (1.02-2.07) 1.37 (0.85-2.19) 1.94 (0.88-4.26)
All-cause death 1.53 (0.80-2.94) 1.37 (0.55-3.42) –c
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; LAIA, long-acting insulin analogue; MI, myocardial infarction; OAD,
oral antidiabetic drug; PIC, potential insulin use candidate.
a Complication-free study cohort is defined as patients without diabetes-related complications (a) at 1 year before index date and (b) before stable use of
fourth-line insulin (or basal insulin alone or LAIAs alone) in the fourth-line insulin (or basal insulin or LAIA) users group and of enhanced OAD therapy in
the PIC group. The group of patients initiating fourth-line basal insulin alone was a subgroup of patients initiating fourth-line insulin, and the group of
patients initiating fourth-line LAIAs alone was a subgroup of patients initiating fourth-line basal insulin alone.
b CVD composite included myocardial infarction, cerebrovascular diseases, heart failure, ischaemic heart disease, arrhythmia, arteriosclerotic cardiovascular
disease, aortic aneurysm, cardiogenic shock and cardiac arrest.
c HR could not be calculated because of the small number of events.
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4.2 | Role of hypoglycaemia in relationship between
insulin therapy and clinical outcomes
Hypoglycaemia is a major undesired effect of insulin therapy, and may
play a role in a causal pathway between insulin therapy and risks of
CVD and mortality. There is supporting evidence linking hypoglycaemia
with increased risks of CVD and mortality in patients with T2DM or
prediabetes,47–51 but one study reported no significant relationship
between severe/symptomatic hypoglycaemic events and CVD-specific/
all-cause mortality in patients with T2DM starting insulin therapy.52 In
the present study we found that the increased risks of clinical outcomes
associated with insulin therapy became lower or even vanished after
hypoglycaemia was adjusted for in the analyses, which provides the
supporting evidence for the potential effect of hypoglycaemia on risks
of CVD and mortality, and indicates the use of insulin per se may not be
associated with increased risks of CVD and mortality (Table 2,
Table S7). Considering all possible efforts will be made to minimize or
avoid hypoglycaemia, such findings should reassure health professionals
who may be reluctant to start insulin therapy because of the perception
that it will have negative impacts on risks of CVD and mortality.
4.3 | Effects of initiating different types of insulin
versus non-insulin therapy on clinical outcomes
Basal insulins, especially LAIAs, lead to a lower risk of hypoglycaemia
than other types of insulin.53,54 Considering that hypoglycaemia may
contribute to CVD risk, it would be worth further assessing the effects
of LAIAs versus other types of insulin or non-insulin therapy in
T2DM; however, there are limited data on this topic. The ORIGIN
trial11 showed that glargine compared with non-insulin therapy had a
neutral effect on cardiovascular outcomes. Another study using Swed-
ish national registries19 demonstrated that second-line treatment
using LAIAs versus DPP-4 inhibitors had a neutral effect on
fatal/non-fatal CVDs and all-cause death, and that, compared with
individual propensity-score-matched DPP-4 inhibitor users, users of
LAIAs experienced a neutral effect on fatal/non-fatal CVD and all-
cause death, but users of short-acting insulin, pre-mixed insulin and
intermediate-acting human insulin had increased risks. Our subgroup
analyses added supporting evidence to the literature; these results
might justify the suggestion of first considering LAIAs alone as the ini-
tial insulin therapy regimen for patients with T2DM.
4.4 | Strengths and limitations
The present study has several strengths. First, it was based on a
national representative cohort of patients with T2DM, with a long-
term follow-up, and results could be applicable to patients who initi-
ated insulin as a fourth-line antidiabetic treatment, which is a common
prescription pattern of insulin use in real-world clinical practice,4 is a
highly recommended treatment strategy by the ADA for patients with
triple OAD therapy failure,9 and is suggested by Taiwan's NHI pro-
gramme (because insulin is generally more expensive than OADs).
Second, rigorous statistical approaches were used to minimize com-
mon potential biases, including confounding by indication, selection
bias and immortal-time bias, to ensure causal inference. Third, a series
of sensitivity and subgroup analyses were conducted to ensure the
robustness of study findings. Particularly, we further broke down dif-
ferent types of insulin to analyse the effects of using LAIAs, which
may fill a research gap in previous studies.
Several limitations should also be acknowledged. First, we used
PSM to control for patient characteristics between study groups, but,
like any study using administrative claims data, the residual effects
attributable to unmeasured confounders could not be avoided. Selection
bias may occur when the choice of initiating fourth-line insulin or
enhancing OAD therapy is made through decisions based on physician–
patient discussions. Moreover, data on indicators of diabetes manage-
ment, such as glycated haemoglobin, blood pressure or lipids, were una-
vailable in Taiwan's NHIRD. However, the duration and severity of
T2DM, the use of OAD regimens and CVD-related medications, and the
status of medical comorbidities were similar between study groups at
baseline in our cohort study. Although a prospective RCT can overcome
the potential confounding by measured or unmeasured covariates, there
may be less motivation for initiation of an RCT to evaluate the fourth-
line antidiabetic treatment options. Second, we targeted insulin use as a
fourth-line antidiabetic treatment, which would make our results unsui-
table for explaining the effects of insulin initiation as monotherapy,
second-line or third-line treatment. Third, the generalizability of our
study findings may be limited to countries with universal health insur-
ance. Lastly, the glucagon-like peptide-1 receptor agonist liraglutide and
the sodium-glucose co-transporter-2 inhibitor empagliflozin were not
available in Taiwan's NHI programme until 1 October 2012 and 1 May
2016, respectively, and thus our analyses did not possess sufficient
power to assess the effects of these drugs on study outcomes because
very few patients (<0.01%) were prescribed these drugs.
In summary, our findings have important therapeutic implications,
supporting the current clinical recommendations to initiate insulin
therapy for patients with T2DM with triple OAD therapy failure and
to provide comprehensive education on avoiding and treating hypo-
glycaemia in any insulin-treated patients. Future prospective trials are
warranted to confirm our findings, especially the potential benefits of
using LAIAs in T2DM on CVD and mortality.
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